IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 79.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,430 shares of the company’s stock after acquiring an additional 8,609 shares during the period. Mutual of America Capital Management LLC’s holdings in IDEXX Laboratories were worth $8,160,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in IDXX. GAMMA Investing LLC lifted its holdings in IDEXX Laboratories by 59,810.7% in the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company’s stock valued at $3,856,950,000 after acquiring an additional 916,898 shares during the last quarter. Principal Financial Group Inc. boosted its stake in IDEXX Laboratories by 58.3% during the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock worth $472,865,000 after buying an additional 414,802 shares during the period. Alyeska Investment Group L.P. purchased a new position in IDEXX Laboratories during the fourth quarter worth about $156,412,000. BNP Paribas Financial Markets boosted its stake in IDEXX Laboratories by 221.3% during the fourth quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company’s stock worth $182,459,000 after buying an additional 303,966 shares during the period. Finally, Bessemer Group Inc. boosted its stake in IDEXX Laboratories by 1,708.8% during the fourth quarter. Bessemer Group Inc. now owns 229,246 shares of the company’s stock worth $94,779,000 after buying an additional 216,572 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on IDXX. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a research note on Tuesday, July 1st. They set a “buy” rating and a $625.00 target price for the company. JPMorgan Chase & Co. increased their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an “overweight” rating in a research note on Monday. BTIG Research increased their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley set a $722.00 target price on shares of IDEXX Laboratories and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, July 12th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $623.56.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director directly owned 1,801 shares in the company, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Down 2.8%

Shares of NASDAQ:IDXX opened at $624.19 on Thursday. The firm’s 50 day moving average price is $539.63 and its 200 day moving average price is $476.14. The stock has a market cap of $50.20 billion, a price-to-earnings ratio of 51.97, a price-to-earnings-growth ratio of 4.32 and a beta of 1.49. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The company has a quick ratio of 0.81, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm’s revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.44 earnings per share. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.